

Managing Director's Presentation

Annual General Meeting 25 November 2021

Dr Colin Biggin

Disclaimer

Introduction

This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (**Clarity** or the **Company**) and contains summary information about Clarity and the business conducted by it as at 25 November 2021. The information in this presentation is for general informational purposes only, does not purport to be complete or comprise all information which a shareholder or potential investor may require in order to determine whether to deal in Clarity shares. It should be read in conjunction with the Company's IPO prospectus and other periodic and continuous disclosure announcements lodged with the ASX.

This presentation is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (Act) or other offer document under Australian law or the law of any other jurisdiction, including the United States.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and the opinions expressed are fair and reasonable, none of Clarity, nor its advisers (Advisers) nor their respective affiliates, related bodies corporate (as defined in the Act) or securityholders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) make any representation or warranty to, or takes responsibility for, the content of this presentation, and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, the Limited Parties disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

Forward looking statements

The information contained in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Clarity's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "believe", "expect", "project", "predict", "intend", "propose", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of Clarity. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by Clarity about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding Clarity's present and future business strategies and the political, regulatory and economic environment in which Clarity will operate in the future, and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance. Actual results from any clinical trial may vary from any result that is anticipated. Under no circumstances will anything in this presentation create an implication that there has been no change in the affairs of the Company since the date of this presentation.

The actual results or performance of Clarity may be materially different from the results or performance expressed or implied by such forward-looking statements.

No representation, warranty or assurance (express or implied) is given or made in relation to any forwardlooking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur. Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in Clarity (Securities) not does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Investors must undertake their own independent investigations, consideration and evaluation. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act).

Clarity recommends that potential investors consult their professional advisors as an investment in Clarity is subject to investment and other known and unknown risks, some of which are beyond the control of Clarity or its directors and therefore any investment is considered to be speculative in nature.

Market and industry data and other information

Certain market and industry data and other information used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives or its advisers have independently verified, or can assure investors as to the accuracy of, any market or industry data or other information provided by third parties or industry or general publications. Photographs and diagrams used in this presentation that do not have descriptions are for illustration only and should not be interpreted to mean that any person shown in them endorses this presentation are illustratives or that the assets shown in them are owned by the Company. Diagrams used in this presentation are illustrative and used and the drawn to scale.

General

Statements made in this presentation are made only as at the date of this presentation. The information in this presentation remains subject to change without notice. The Company may in its absolute discretion, but without being under any obligation to do so, update or supplement this presentation. Any further information will be provided subject to the terms and conditions contained in this Disclaimer.



Clarity's clinical development pipeline

Clarity's products are progressing through Phase I and Phase II clinical trials with two open IND applications that received clearance to proceed to clinical trials from the FDA, two RPDDs and two ODDs from the FDA

Indication	Product		Discovery	Preclinical	Phase I	Phase 2	Phase 3
Prostate Cancer	SAR-bisPSMA	Theranostic					
	SAR-bisPSMA	Diagnostic		NK.			
	SAR-BBN	Diagnostic		#:			
	SAR-BBN	Theranostic					
Neuroblasłoma	SARTATE	Theranostic					
	SARTATE	Diagnostic					
NETs	SARTATE	Diagnostic		*			
Pan cancer (GRPr positi∨e tumours)	SAR-BBN	Diagnostic		*			
SAR Discovery Platform	Undisclosed	Undisclosed	*				
	Undisclosed	Undisclosed	*				

Robust clinical trial strategy

- Developing products for both rare and large indications with high unmet needs
- Focus on high quality clinical sites and experienced investigators
- Positioning products to maximise opportunity in current treatment paradigms
- Targeting the lucrative US market for first product approvals


Current progress

*Note clinical development pipeline is indicative only, subject to review. **All US studies are conducted under IND



US prostate cancer in numbers

1:8



American Cancer Society, Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021.


CLARITY

2) Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017. MMWR Morb Mortal Wkly Rep 2020;69:1473–1480.

SAR-bisPSMA: Pre-clinical data

SAR-bisPSMA has ideal product characteristics for a radiopharmaceutical

High uptake and retention in tumour




Preclinical biodistribution study demonstrating high uptake and retention of 64Cu SAR-bisPSMA in tumours with rapid clearance from non-target

organs

Zia et al., 2019. Ang.Chem

Significant anti-tumour effect




Preclinical efficacy study with increasing activity of 67Cu SAR**bisPSMA** (colours) demonstrating dose response

15 MBg⁶⁷Cu-CuSARbisPSMA 15 (1) + 15 (15) MBq⁶⁷Cu-CuSARbisPSMA

McInnes et al., 2020. JNM

Rapid kidney clearance of non-bound activity



24 hr 1 hr Tumour targeting and superior retention over 24 hours

PET images showing ⁶⁴Cu SAR**bisPSMA** targeting to tumours over time and rapid kidney clearance

'Bis-PSMA' The term Bis is used to denote the presence of two identical but separate complex groups in one molecule Activity/g tumou Injected 2 T= 1h T= 24h T= 1h T= 24h PSMA-617 SAR-bisPSMA From Benesova et al 2015 From Zia et al 2019




SAR-bisPSMA: Current clinical trials

SECURE: Systemic Copper theranostics in prostate cancer (NCT04868604)

A Phase I/IIa study of ⁶⁴Cu SAR-bisPSMA and ⁶⁷Cu SARbisPSMA for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (mCRPC)

- Theranostic multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients
- Recruiting in the US under an open IND
- The trial employs diagnostic PET imaging with ⁶⁴Cu SARbisPSMA for selection of patients suitable for therapy cycles with ⁶⁷Cu SAR-bisPSMA

SECuRE study design



PR 🕸 PELLER

PROPELLER: PET Imaging of Participants With Confirmed Prostate Cancer (NCT04839367)

A Phase I multi-centre, blinded review, dose ranging, non-randomised study in 30 patients across Australia

- Recruiting in early phase prostate cancer in participants with untreated, confirmed prostate cancer and planned for radical prostatectomy
- Compare ⁶⁴Cu SAR-bisPSMA to ⁶⁸Ga PSMA-11, the Standard of Care for prostate cancer imaging in Australia

PROPELLER study design



SAR-bisPSMA mCRPC therapy

LARITY

Preliminary imaging results from the dosimetry phase of the theranostic SECuRE clinical trial

PET scans in a patient with metastatic castrate-resistant prostate ⁶⁴Cu SARcancer imaged over multiple timepoints between 1 and 72 hours post **bisPSMA PET/CT** administration of 64Cu SAR-bisPSMA (Normalized Voxel Intensity) 12hr 64Cu SAR-72h post injection 1h post injection 12h post injection 24h post injection 48h post injection bisPSMA PET/CT

Comparison of 1h ⁶⁴Cu SARbisPSMA PET with ^{99m}Tc-MDP **Bone Scan**



Fused Sagittal

1h 64Cu SAR**bisPSMA PET**


^{99m}Tc-MDP WB Bone Scan

SAR-Bombesin in prostate cancer

Detection of PSMA-negative prostate cancer (PC)

- ~10% of prostate cancer patients do not express PSMA
- PSMA negative prostate cancer patients will not respond to PSMA imaging or therapy
- 75-100% of prostate cancer patients express GRPr
- Diagnosis and treatment of these patients with TCTs targeting GRPr opens new possibilities
- Significant clinical synergies with existing SAR-bisPSMA program for clinical and development and regulatory affairs
- On-track to commence a US diagnostic study in 2022 under an IND

⁶⁸Ga PSMA-11 (top) images of a PSMA-negative patient with clinical signs of PC (a rising PSA score of 0.16 ng/mL) and ⁶⁴Cu SAR-Bombesin PET/CT images of the same patient (bottom)





⁶⁸Ga PSMA-11 (top) images of a PSMA-

negative patient with history of PC (a rising PSA

score of 25 ng/mL) and ⁶⁴Cu SAR-Bombesin PET/CT images of the same patient (bottom)

SAR-Bombesin: A pan-cancer target

SAR-Bombesin is a highly targeted pan-cancer theranostic radiopharmaceutical being developed for identifying and selecting patients for subsequent treatment of their cancers that express gastrin releasing peptide receptor (GRPr)

SAR-Bombesin

- GRPr is a receptor that is overexpressed in a number of cancers including prostate, breast, colon, gastric, glioma, pancreatic, small cell lung and non-small cell lung cancer, as well as renal cell cancer
- 75%-100% of prostate cancers express GRPr
- 83% of estrogen receptor (ER) positive breast cancers express GRPr
- ⁶⁴Cu/⁶⁷Cu SAR-Bombesin is under investigation as a theranostic pairing to treat breast and prostate cancer patients with tumours that express GRPr

T = 1 hour T = 4 hours T = 24 hours Control aroup ູ ພິ 1500-⁶⁷Cu-SAR-Bombesin treated aroup Volur 1000-Tumour Efficacy of ⁶⁴Cu SAR 500 Bombesin in a mouse model of prostate cancer 15 20 25 30 35 40 45 50 time after injection (days)

⁶⁷Cu SAR-Bombesin has demonstrated an anti-tumour effect in preclinical models of prostate cancer, when compared to the control group




⁶⁴Cu SAR-Bombesin in hormone positive metastatic breast cancer

SAR-Bombesin in metastatic breast cancer

C-BOBCAT: Recruitment closed

First-in-human pilot trial assessment of the diagnostic value of ⁶⁴Cu SAR-Bombesin PET/CT imaging for staging of hormone positive breast cancer patients with metastatic disease in comparison with standard of care imaging (CT, bone scan and ¹⁸F FDG PET/CT)

- Study Sponsor: St Vincent's Hospital, Sydney
- PI: Prof. Louise Emmett
- Preliminary data from the C-BOBCAT trial shows that ⁶⁴Cu SAR-Bombesin is highly avid with a high tumour volume compared to ¹⁸F FDG in some patients
- Preliminary results indicate ⁶⁴Cu SAR-Bombesin may have a role in imaging patients with hormone positive breast cancer





SARTATE[™] – next generation theranostic

SARTATE™ is a highly targeted theranostic radiopharmaceutical which is being developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2 (SSTR2)

Target benefits


- Targets tumours that express somatostatin receptor 2 • (SSTR2)
- Well characterised and substantiated peptide •
- Octreotate, synthetic SSTR analogue, has been in • many thousands of patients to date
- Expectation of clinical benefit (efficacy) to patients •

Current clinical development

- ⁶⁴Cu SARTATETM for the management of neuroblastoma ٠
- ⁶⁷Cu SARTATETM for the treatment of neuroblastoma ٠
- ⁶⁴Cu SARTATETM for the management of NETs

Future opportunities

Other SSTR2 positive diseases, including but not ٠ limited to pancreatic and gastrointestinal cancer, pulmonary NETs, and meningiomas.





SARTATE[™]: Clinical trials

SARTATE[™] CL04: ⁶⁷Cu-SARTATE[™] Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma (NCT 04023331)

- ⁶⁴Cu/⁶⁷Cu SARTATE[™] Phase I/IIa trial in high-risk neuroblastoma in the US with up to 34 patients
- Multi-centre, dose-escalation, open label, nonrandomised, theranostic clinical trial.

Neuroblastoma is one of the most aggressive childhood cancers

- 800 new cases each year in the US and the most common cancer in infants
- Neuroblastoma accounts for approximately 13% of paediatric cancer mortalities
- Approximately 84% of neuroblastomas express SSTR2



DISCO: Diagnostic Imaging Study of Copper-64 SARTATE using PET on patients with known or suspected NETs (<u>NCT 04438304</u>)

- Assessing the performance of imaging agent ⁶⁴Cu SARTATETM in participants with known or suspected gastroenteropancreatic NETs as a potential new way to help diagnose and manage NETs
- Phase II study recruiting in 63 patient trial at four sites in Australia with ⁶⁴Cu SARTATE[™] manufactured centrally in Australia
- Aims to capture and highlight the significant advantages of the longer half-life (12.7 hours) of copper-64, related to imaging and product supply which are relevant to Clarity's entire pipeline of products in development
 - Comparing diagnostic performance of ⁶⁴Cu SARTATETM at 4 and 20 hours to the current standard of care, ⁶⁸Ga DOTATATE, at one hour



Clinical development pipeline - 12 month progress

Clarity is rapidly progressing its pipeline of TCT products through clinical development as the Company anticipates the achievement of significant milestones in the next year

Indication	Product		Discovery	Preclinical	Phase I	Phase 2	Phase 3	Next Milestone
Prostate Cancer	SAR-bisPSMA	Theranostic						First therapy treatment
	SAR-bisPSMA	Diagnostic		AK.				50% recruitment in PROPELLER
	SAR-BBN	Diagnostic		*				Open IND for US study
	SAR-BBN	Theranostic	Ĭ					Open IND for US study
Neuroblastoma	SARTATE	Theranostic						Advance to cohort 2
	SARTATE	Diagnostic						Open IND for US study
NETs	SARTATE	Diagnostic		***				50% recruitment in DISCO
Pan cancer (GRPr positive tumours)	SAR-BBN	Diagnostic		*		*		First patient treated
SAR Discovery Platform	Undisclosed	Undisclosed	*					
	Undisclosed	Undisclosed	*					

Current progress 12 month progre



*Note clinical development pipeline is indicative only, subject to review. **All US studies are conducted under IND 13

Slide from Clarity AGM 2020

Clarity delivered on all our goals for 2021 from the last AGM

Clarity in 2021

Five active clinical trials generating significant human trial data across all programs

- Prostate therapy data from US sites
- Prostate diagnostic data from Australia
- Neuroblastoma diagnostic and therapy data USA
- Neuroendocrine tumours diagnostic AUS
- Breast cancer data with SAR Bombesin
- Prostate cancer data with SAR Bombesin

Opening INDs for 2 theranostic programs with the USA FDA (SARTATE and SAR bisPSMA)

Continued strengthening of manufacturing capabilities


Development of new agents to further our pipeline



 (\checkmark)



Inflection points to Q4 2022



Contact details

Dr Alan Taylor Executive Chairman E: alan.taylor@claritypharm.com

Alan has been instrumental in the growth of Clarity over the last seven years, leading the Company from a start-up with no employees to where it is today, and heavily involved in all areas of the company. He has approximately 15 years of investment banking experience focused predominantly on the life sciences, with experience in capital raisings, mergers and acquisitions, and general corporate advisory, and has been involved in approximately \$2 billion worth of transactions.



Dr Colin Biggin Managing Director E: colin.biggin@claritypharm.com

Colin has over 15 years of radiopharmaceutical development and commercialisation experience. He served with Algeta ASA from 2006-2015 during the development and commercialisation of Xofigo (radium-223) for metastatic prostate cancer and consulted to a range of biotech's and large pharma companies developing radiopharmaceuticals prior to joining Clarity in 2017.